FDA OKs molecular Dx test to detect HAI-causing bacteria

07/30/2013 | GenomeWeb Daily News (free registration)

The FDA has cleared IntelligentMDx to market an assay used to detect certain genes linked to vancomycin-resistant enterococci, which can trigger hospital-acquired infections in the bloodstream, surgical wounds and the urinary tract. The assay, which runs on Abbott's m2000 diagnostic platform, takes less than three hours to generate results for as many as 46 samples.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA